Current Report Filing (8-k)
May 08 2019 - 4:32PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): May 8, 2019
REGEN
BIOPHARMA, INC.
(Exact
name of small business issuer as specified in its charter)
Nevada
|
45-5192997
|
(State
or other jurisdiction of incorporation or organization)
|
(I.R.S.
Employer Identification No.)
|
Commission
File No. 333-191725
4700
Spring Street, St 304, La Mesa, California 91942
(Address
of Principal Executive Offices)
(619)
702 1404
(Issuer’s
telephone number)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item
7.01. Regulation FD Disclosure.
On
May 8, 2019 Regen BioPharma, Inc., a Nevada corporation (the “Company”) discovered that false information was being
disseminated through Market Watch stating that the Company had initiated a reverse merger with Aregen Bioscience Inc. As of May
8, 2019 the Company is currently not in any discussions with any other entities regarding any business combination including,
but not limited to, a reverse merger or acquisition.
Item
8.01. Other Events
On
May 8, 2019 Regen BioPharma, Inc., a Nevada corporation (the “Company”) discovered that false information was being
disseminated through Market Watch stating that the Company had initiated a reverse merger with Aregen Bioscience Inc. As of May
8, 2019 the Company is currently not in any discussions with any other entities regarding any business combination including ,
but not limited to, a reverse merger or acquisition.
Item
9.01 Exhibits
Exhibit
99.1 Press Release
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
REGEN
BIOPHARMA, INC.
|
|
|
Dated: May 8, 2019
|
By:
/s/
David Koos
|
|
David Koos
|
|
Chief Executive Officer
|
Regen Biopharma (PK) (USOTC:RGBPP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Regen Biopharma (PK) (USOTC:RGBPP)
Historical Stock Chart
From Apr 2023 to Apr 2024